Zura Bio Limited(ZURA)

Biotechnology · Henderson, NV

$3.96+0.03 (+0.76%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T21:48:44.558Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:48:44.558Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 376,190,932
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 205,134,000
TTM operating EBITDA · period ending 2026-06-30: -92,689,000

FMP input reference: 48a9c173a70739b1093346a936f860d9c8f80d7eeb2565194c7199b3c596865c

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ZURA EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

ZURA Competitors' EV/EBITDA Ratio

ZURA

Zura Bio Limited

Current

Market Cap

$376.19M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CGC

Canopy Growth Corporation

vs ZURA

Market Cap

$376.01M

EV/EBITDA Ratio

N/A

TTM Avg

682.46x

3Y Avg

682.46x

5Y Avg

682.46x

KYTX

Kyverna Therapeutics, Inc.

vs ZURA

Market Cap

$374.50M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OFIX

Orthofix Medical Inc.

vs ZURA

Market Cap

$380.37M

EV/EBITDA Ratio

4.27x

TTM Avg

129.81x

3Y Avg

151.06x

5Y Avg

73.64x

ARCT

Arcturus Therapeutics Holdings Inc.

vs ZURA

Market Cap

$369.50M

EV/EBITDA Ratio

N/A

TTM Avg

10.71x

3Y Avg

10.71x

5Y Avg

10.71x

RGNX

REGENXBIO Inc.

vs ZURA

Market Cap

$385.15M

EV/EBITDA Ratio

N/A

TTM Avg

7.49x

3Y Avg

7.49x

5Y Avg

18.24x

IRD

Opus Genetics, Inc.

vs ZURA

Market Cap

$361.64M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FENC

Fennec Pharmaceuticals Inc.

vs ZURA

Market Cap

$359.53M

EV/EBITDA Ratio

N/A

TTM Avg

40.38x

3Y Avg

40.38x

5Y Avg

40.38x

Shoulder Innovations, Inc.

vs ZURA

Market Cap

$396.93M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ARTV

Artiva Biotherapeutics, Inc.

vs ZURA

Market Cap

$355.43M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Zura Bio Limited (ZURA)	$376.19M	N/A	N/A	N/A	N/A
Canopy Growth Corporation (CGC)vs ›	$376.01M	N/A	682.46x	682.46x	682.46x
Kyverna Therapeutics, Inc. (KYTX)vs ›	$374.50M	N/A	N/A	N/A	N/A
Orthofix Medical Inc. (OFIX)vs ›	$380.37M	4.27x	129.81x	151.06x	73.64x
Arcturus Therapeutics Holdings Inc. (ARCT)vs ›	$369.50M	N/A	10.71x	10.71x	10.71x
REGENXBIO Inc. (RGNX)vs ›	$385.15M	N/A	7.49x	7.49x	18.24x
Opus Genetics, Inc. (IRD)vs ›	$361.64M	N/A	N/A	N/A	N/A
Fennec Pharmaceuticals Inc. (FENC)vs ›	$359.53M	N/A	40.38x	40.38x	40.38x
Shoulder Innovations, Inc. (SI)vs ›	$396.93M	N/A	N/A	N/A	N/A
Artiva Biotherapeutics, Inc. (ARTV)vs ›	$355.43M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics